Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 3Urologic Diseases 2Urinary Bladder Diseases 2Carcinoma, Transitional Cell 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 37Carboplatin 26Radiotherapy 23Cisplatin 19Paclitaxel 18Erlotinib Hydrochloride 18Docetaxel 15Gemcitabine 14Pemetrexed 13Etoposide 12osimertinib 11Nivolumab 11durvalumab 9atezolizumab 9Radiosurgery 8Magnetic Resonance Spectroscopy 8Cetuximab 7Specimen Handling 6Cyclophosphamide 6130-nm albumin-bound paclitaxel 6Taxes 5Immunoglobulin G 5Gefitinib 5Biopsy 5Bevacizumab 5fludarabine 4Radiation 4Ipilimumab 4Disulfides 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lung Neoplasms × vofatamab × Clear all
NCT05363605 2023-12-19

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Fusion Pharmaceuticals Inc.

Phase 1/2 Terminated
6 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡